BETAThis is a new independent transparency project, not an official government website. The data is sourced from public registers and may contain errors, so always verify against the official source. If you find a problem, please report it here.
Medicines Discovery Catapult (MDC) is an independent, not-for-profit innovation centre for drug discovery and part of the Catapult Network established by Innovate UK.
MDC's vision is to reshape drug discovery for patient benefit by transforming great UK science into better treatments through partnership. It supports drug discovery innovators by making world-class expertise, facilities, complex technologies, and advanced analytics accessible to enable successful medicines discovery.
MDC develops pioneering, impactful R&D collaborations across biotech, academia, technology companies, charities, and global pharma. It brings these communities together in active, focused national programmes that target high-risk areas of patient need.
This requirement originates from the Partnership Team at Medicines Discovery Catapult (MDC), which includes national programmes across neuroscience and infection, virtual R&D, and complex medicine. The team plays a central role in enabling and accelerating UK drug discovery by identifying unmet needs, supporting ecosystem coordination, and helping to navigate the scientific and translational complexities of areas such as diseases of the brain.
To fulfil its role effectively, the team must remain consistently informed about recent scientific developments, innovation opportunities, and areas of commercial promise. This enables MDC to identify and shape collaborative initiatives, support investment cases, and build strategies aligned to evolving national and global health priorities.
The current emphasis has been on neuroscience, particularly neurodegenerative diseases, mental health, and drug discovery and delivery. Previous work has included:
Building on this initial work, MDC now seeks to expand the scope and focus of the landscape activity to include:
MDC requires a consultant to:
Deliverables would be specific for each project, but it is expected that they could include:
The supplier must have a proven track record of delivering high quality technical writing, with strong communication skills. A minimum of 5 years' experience in technical or scientific writing, with demonstrable experience in life sciences.
Access to proprietary databases to access the relevant datasets useful for the specific projects (including OpenAlex, Europe PMC, PubMed, CrossRef, Dimensions, Lens.org (patents), ClinicalTrials.gov, WHO ICTRP, NICE Evidence). Expertise in the use of AI and language models to automate and classify data retrieval and apply thematic analyses Proven ability to synthesise scientific and commercial insights for strategic use. Previously work in areas relevant to MDC strategic mission.
No supplier information available.
This procurement was divided into 1 lots, each awarded separately.
| Lot | Value | Status |
|---|---|---|
| Lot 1 Feb 2026 – Aug 2026 | £75,000 | active |
Weightings from the notice.